4.6 Article

Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer

Journal

NPJ BREAST CANCER
Volume 7, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41523-021-00324-7

Keywords

-

Categories

Funding

  1. National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2017R1D1AB03033362, NRF-2018R1A6A1A03023718, 2020R1A2C1003378]
  2. National Research Foundation of Korea [2020R1A2C1003378] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Adipocytes influence breast cancer behavior by releasing fatty acids into the tumor microenvironment. CD36 serves as a key mediator in the import and metabolism of fatty acids in cancer cells, interacting with STAT3 to drive tumor progression. Inhibition of CD36 and FABP4 induces apoptosis in tumor cells, indicating their potential as therapeutic targets in the tumor microenvironment.
Adipocytes influence breast cancer behaviour via fatty acid release into the tumour microenvironment. Co-culturing human adipocytes and breast cancer cells increased CD36 expression, with fatty acid import into breast cancer cells. Genetic ablation of CD36 attenuates adipocyte-induced epithelial-mesenchymal transition (EMT) and stemness. We show a feedforward loop between CD36 and STAT3; where CD36 activates STAT3 signalling and STAT3 binds to the CD36 promoter, regulating its expression. CD36 expression results in metabolic reprogramming, with a shift towards fatty acid oxidation. CD36 inhibition induces de novo lipogenesis in breast cancer cells. Increased CD36 expression occurs with increased FABP4 expression. We showed that CD36 directly interacts with FABP4 to regulate fatty acid import, transport, and metabolism. CD36 and FABP4 inhibition induces apoptosis in tumour cells. These results indicate that CD36 mediates fatty acid import from adipocytes into cancer cells and activates signalling pathways that drive tumour progression. Targeting CD36 may have a potential for therapy, which will target the tumour microenvironment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available